Showing results (2141-2150 of 6,416) with videos related to

Sort By:
Pageof 642
World Journal of Urology|January 17, 2025
Tunica vaginalis or dartos as second layer coverage for distal and mid-shaft penile hypospadias, quo vadis?Mohamed Ramez, Abdelwahab Hashem, Mahmoud Bazeed, et al.
World Journal of Urology|January 15, 2025
Research progress on intratumoral microorganisms in renal cancerJiankun Zhang, Keyuan Lou, Junpeng Chi, et al.
World Journal of Urology|January 10, 2025
Deep learning-based lymph node metastasis status predicts prognosis from muscle-invasive bladder cancer histopathologyQingyuan Zheng, Panpan Jiao, Rui Yang, et al.
World Journal of Urology|January 13, 2025
Water vapor thermal therapy for treatment of lower urinary tract symptoms due to large benign prostatic hyperplasia (≥ 80 g)Christopher Agüero, Thibaut Long Depaquit, Alessandro Uleri, et al.
World Journal of Urology|December 31, 2024
Functional outcomes of single-session holmium laser enucleation of the prostate and high-intensity focused ultrasound in management of patients with prostate cancer and enlarged prostate: results from a pilot studyJessica Delgado, Joao G Porto, Ansh Bhatia, et al.
World Journal of Urology|December 31, 2024
Identifying optimal candidates for active surveillance in low-grade intermediate-risk non-muscle invasive bladder cancerPaolo Zaurito, Pietro Scilipoti, Mattia Longoni, et al.
World Journal of Urology|January 4, 2025
Exploring the therapeutic potential of PACAP in Hunner-type Interstitial CystitisHanwei Ke, Lin Zhu, Qi Wang, et al.
World Journal of Urology|January 3, 2025
Can we predict postoperative fever and urinary tract ınfection after retrograde ıntrarenal surgery? Results of a case control matching multicentric RIRSearch study groupMurat Akgül, Oktay Özman, Cem Başataç, et al.
World Journal of Urology|January 3, 2025
PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCGFlorus C de Jong, Vebjørn Kvikstad, Robert F Hoedemaeker, et al.
World Journal of Urology|January 3, 2025
Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and locally advanced prostate cancer: a multicenter, open-label, single-arm, phase II trialXuyu Zhang, Feng Zhou, Tong Lu, et al.
Pageof 642